The authors write that these differences among Veterans Affairs (VA) populations could reflect variability across the medical centers in terms of quality of care, adherence to evidence-based treatment and screening guidelines, access to urgent care, posthospitalization care protocols, chronic disease management, and access to specialty care, social work services, and behavioral health care.
In a paper published today in JAMA Cardiology, Peter W. Groeneveld, MD, MS, of the Veterans Affairs Medical Center, Philadelphia, and colleagues report that death rates for patients with ischemic heart disease (IHD) and chronic heart failure (CHF) vary widely across the Veterans Affairs (VA) system.1 Those variations, they say, may point to important differences in care provided at VA medical centers.
Although the VA is a highly integrated system, some prior research has suggested that variation in health outcomes occurs across the VA; in order to assess whether there are substantial differences in the outcomes of patients with IHD and CHF, which are prevalent in the VA healthcare system, the research team conducted a cohort study among 930,079 patients with IHD and 348,015 patients with CHF who received treatment at 138 medical centers between 2010 to 2014. The patients were predominantly white males.
They found that the overall annual mortality rate in the IHD cohort was 7.4% and that the risk-standardized mortality rate for this group ranged from 5.5% (95% CI, 5.2%-5.7%) at the medical center with the lowest mortality to 9.4% (95% CI, 9.0%-9.9%) at the facility with the highest mortality.
In the CHF cohort, the overall annual mortality rate was 14.5%, which also varied across centers, with the lowest-mortality facility having a rate of 11.1% (95% CI, 10.3%-12.1%) and the highest-mortality center having a rate of 18.9% (95% CI, 18.3%-19.5%).
Mean composite IHD and CHF standardized survival scores were slightly higher in the East and Midwest than in the West and South of the country. The researchers observed a weak (R2 = .06) but statistically significant (P = .005) association between the composite cardiovascular outcome measure and the VA’s Strategic Analytics for Improvement and Learning star system for quality measurement, but mortality rates for these cohorts were not associated with 30-day mortality rates and were only weakly associated with hospitalized heart failure 30-day mortality rates (R2 =.16; P <.001).
The authors write that these differences among VA populations could reflect variability across the medical centers in terms of quality of care, adherence to evidence-based treatment and screening guidelines, access to urgent care, posthospitalization care protocols, chronic disease management, and access to specialty care, social work services, and behavioral health care.
In a linked editorial,2 Paul A. Heidenreich, MD, MS, called the findings “provocative” and said that “the demand for quality has outpaced our ability to measure it.” According to Heidenreich, pay-for-performance programs for IHD and CHF that focus on hospitalization and the following 30 days may be part of the problem, because hospital-centric views of quality do not adequately address most patients with chronic diseases who spend more time outside the hospital than in it.
According to Heidenreich, the next steps for improvement include better data sharing to track patients across health systems, additional health services research, and increased analytical expertise among staff in health systems.
References
1. Groeneveld PW, Medvedeva EL, Walker L, Segal AG, Richardson DM, Epstein AJ. Outcomes of care for ischemic heart disease and chronic heart failure in the Veterans Health Administration [published online May 16, 2018]. JAMA Cardiol. doi: 10.1001/jamacardio.2018.1115.
2. Heidenreich PA. In pursuit of better measures of quality of care [published online May 16, 2018]. JAMA Cardiol. doi: 10.1001/jamacardio.2018.1204.
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Accountable Care Organization Initiatives to Improve the Cost and Outcomes of Specialty Care
April 2nd 2024Engaging specialty physicians is an emerging area of focus for Medicare accountable care organizations. Enhanced data on specialist costs and outcomes are essential to addressing alignment challenges.
Read More
Increasing Lp(a) Awareness for Better Cardiovascular Health: Dr Mary McGowan
March 24th 2024For Lp(a) Awareness Day, Mary McGowan, MD, FNLA, chief medical officer of the Family Heart Foundation, highlights how most people with elevated Lp(a) are completely unaware that they have this increased risk and calls for increased testing.
Read More